Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Apalutamide with Itraconazole or Gemfibrozil
NCT02230033Phase 1Completed
- Sponsor
- Aragon Pharmaceuticals
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apalutamide in prostate cancer (PCa) (3 arms), sponsored by Aragon Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration, Time to Reach Maximum Concentration and 6 more. Started Sep 2014; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02230033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02230033.